ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
흡입형 생물학적 제제 시장 규모는 향후 몇 년 동안 빠르게 성장하여 2029년까지 16.0%의 연평균 성장률로 59억 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 전 세계 고령화 인구 증가, 신흥 시장의 의료 인프라 확대, 생물학적 제제 치료에 대한 규제 당국의 지원 확대, 감염성 호흡기질환 사례 증가 등에 기인할 것으로 예상됩니다. 이 기간 동안 예상되는 주요 동향으로는 약물전달 시스템의 발전, 스마트 흡입기 기술의 통합, 에어로졸 과학의 혁신, 생물학적 제제의 발전, 나노입자 기반 캐리어의 발전 등이 있습니다.
호흡기질환의 유병률 증가는 향후 몇 년 동안 흡입형 생물학적 제제 시장의 성장에 크게 기여할 것으로 예상됩니다. 호흡기질환에는 폐 및 호흡기, 기도, 비강, 폐를 포함한 호흡기의 다른 구성요소에 영향을 미치는 질환 및 상태가 포함됩니다. 이러한 질환의 증가는 천식, 만성폐쇄성폐질환(COPD), 폐암과 같은 질환을 악화시키고 유해한 미립자 물질과 오염물질에 노출되는 대기오염의 증가에 기인합니다. 흡입형 생물학적 제제는 표적화된 치료제를 폐에 직접 전달하여 전신 부작용을 줄이면서 염증을 억제하고 폐 기능을 개선하기 때문에 이러한 증상에 특히 효과적입니다. 예를 들어, 2024년 6월 호주 정부 기관인 Australian Institute of Health and Welfare는 2023년 COPD가 전체 질병 부담의 3.6%, 호흡기질환 부담의 50%를 차지할 것이라고 보고했습니다. 이에 따라 호흡기질환의 증가는 흡입형 생물학적 제제 시장을 크게 견인하고 있습니다.
흡입형 생물학적 제제 시장의 주요 기업들은 환자의 순응도를 높이고 더 빠른 혈당 조절을 제공하기 위해 흡입 인슐린과 같은 혁신적인 솔루션 개발에 주력하고 있습니다. 흡입 인슐린은 주사나 인슐린 펌프가 아닌 흡입을 통해 폐에서 혈류로 직접 주입되는 인슐린을 말합니다. 이 방법은 분말 또는 에어로졸화 된 인슐린을 흡입하여 폐에서 흡수되어 혈류로 빠르게 들어가 혈당을 조절하는 방식입니다. 예를 들어, 2025년 2월 인도 제약회사 시프라(Sipra Limited)는 1형 및 2형 당뇨병을 앓고 있는 성인에게 주사바늘을 사용하지 않는 옵션을 제공하는 세계에서 가장 빠른 흡입형 인슐린인 아프레자(Afrezza)에 대해 중앙의약품표준관리기구의 허가를 획득했습니다. 이 초속효성 인슐린은 흡입 후 12-15분 만에 효과가 나타나며, 식사에 대한 자연적 인슐린 반응을 충실하게 모방하여 혈당 조절을 개선합니다. 흡입형 인슐린은 특히 주사에 대한 두려움이 있는 환자들에게 매일 주사를 맞을 때보다 더 편안한 대안이 되어 인슐린 치료 순응도를 높일 수 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 흡입형 생물학적 제제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 흡입형 생물학적 제제 시장 : 성장률 분석
세계의 흡입형 생물학적 제제 시장 실적 : 규모와 성장, 2019-2024년
세계의 흡입형 생물학적 제제 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 흡입형 생물학적 제제 전체 시장(TAM)
제6장 시장 세분화
세계의 흡입형 생물학적 제제 시장 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
펩타이드와 단백질
백신
단클론항체
RNAi 기반 치료법
기타 유형
세계의 흡입형 생물학적 제제 시장 : 제형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
건조 분말 흡입기
정량 분무식 흡입기
네블라이저
기타 제형
세계의 흡입형 생물학적 제제 시장 : 유통 채널별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
병원 약국
소매 약국
온라인 약국
세계의 흡입형 생물학적 제제 시장 : 용도별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
호흡기질환
당뇨병
암
기타 용도
세계의 흡입형 생물학적 제제 시장, 펩타이드와 단백질 종류별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
인슐린
성장호르몬
효소보충요법
기타 펩타이드와 단백질
세계의 흡입형 생물학적 제제 시장, 백신 종류별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
인플루엔자 백신
기타 호흡기 백신
세계의 흡입형 생물학적 제제 시장, 단클론항체 종류별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
호흡기 단클론항체
면역조절 단클론항체
기타 단클론항체
세계의 흡입형 생물학적 제제 시장, RNAi 기반 치료제 종류별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
호흡기질환에 대한 RNA 기반 약제
기타 RNAi 기반 치료법
세계의 흡입형 생물학적 제제 시장, 기타 유형 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
유전자 치료
저분자 흡입제
기타 혁신적인 흡입형 생물학적 제제
제7장 지역별·국가별 분석
세계의 흡입형 생물학적 제제 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 흡입형 생물학적 제제 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
흡입형 생물학적 제제 시장 : 경쟁 구도
흡입형 생물학적 제제 시장 : 기업 개요
Bayer AG Overview, Products and Services, Strategy and Financial Analysis
Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
Novartis AG Overview, Products and Services, Strategy and Financial Analysis
GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Medtronic PLC
Moderna Inc.
Pfizer Inc. and BioNTech SE
Teva Pharmaceuticals
Baxter International
Lonza Group AG
CanSino Biologics Inc.
Cipla Ltd.
Insmed Incorporated
Kamada Pharmaceuticals
Vectura Group plc
F. Hoffmann-La Roche Ltd
Iconovo AB
Synairgen plc
Ab Initio Pharma LLC
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
흡입형 생물학적 제제 시장 2029년 : 새로운 기회를 제공하는 국가
흡입형 생물학적 제제 시장 2029년 : 새로운 기회를 제공하는 부문
흡입형 생물학적 제제 시장 2029년 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
Inhalable biologics are biologic drugs that are delivered through the respiratory tract via inhalation. This method allows for targeted treatment of lung diseases or systemic therapy by directly reaching the lungs, which enhances the drug's effectiveness and minimizes side effects.
The primary types of inhalable biologics include peptides and proteins, vaccines, monoclonal antibodies, RNAi-based therapeutics, and others. Peptide and protein therapeutics are bioactive molecules designed to influence specific cellular pathways or replace deficient proteins. These biologics are available in various dosage forms, such as dry powder inhalers, metered-dose inhalers, nebulizers, and others, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. They are used in the treatment of respiratory diseases, diabetes, cancer, and other conditions.
The inhalable biologics market research report is one of a series of new reports from The Business Research Company that provides inhalable biologics market statistics, including inhalable biologics industry global market size, regional shares, competitors with an inhalable biologics market share, detailed inhalable biologics market segments, market trends and opportunities, and any further data you may need to thrive in the inhalable biologics industry. This inhalable biologic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The inhalable biologics market size has grown rapidly in recent years. It will grow from $2.79 billion in 2024 to $3.25 billion in 2025 at a compound annual growth rate (CAGR) of 16.4%. The growth during the historic period can be attributed to the rising prevalence of respiratory diseases globally, a growing demand for non-invasive delivery methods, increased awareness of the benefits of biologics, and the expanding research and investment in biopharmaceuticals.
The inhalable biologics market size is expected to see rapid growth in the next few years. It will grow to $5.90 billion in 2029 at a compound annual growth rate (CAGR) of 16.0%. The growth during the forecast period can be attributed to the increasing global aging population, the expansion of healthcare infrastructure in emerging markets, growing regulatory support for biologics therapy, and a rise in cases of infectious respiratory diseases. Key trends expected during this period include advancements in drug delivery systems, the integration of smart inhaler technology, innovations in aerosol science, developments in biologic drug formulations, and progress in nanoparticle-based carriers.
The growing prevalence of respiratory disorders is expected to significantly contribute to the growth of the inhalable biologics market in the coming years. Respiratory disorders encompass diseases and conditions affecting the lungs and other components of the respiratory system, including the airways, nasal passages, and lungs. The rise in these conditions is largely attributed to increasing air pollution, which exacerbates ailments such as asthma, chronic obstructive pulmonary disease (COPD), and lung cancer by exposing individuals to harmful particulate matter and pollutants. Inhalable biologics are particularly effective for these conditions as they deliver targeted treatments directly to the lungs, reducing inflammation and improving lung function with fewer systemic side effects. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency in Australia, reported that in 2023, COPD accounted for 3.6% of the total disease burden and 50% of the respiratory disease burden. Consequently, the rise in respiratory disorders is significantly boosting the inhalable biologics market.
Leading companies in the inhalable biologics market are focusing on developing groundbreaking solutions, such as inhaled insulin, to enhance patient compliance and provide faster glycemic control. Inhaled insulin is a form of insulin that is delivered directly into the bloodstream through the lungs via inhalation, rather than through injections or insulin pumps. This method involves inhaling a powder or aerosolized insulin, which is absorbed through the lungs and quickly enters the bloodstream to regulate blood sugar levels. For example, in February 2025, Cipla Limited, an India-based pharmaceutical company, received regulatory approval from the Central Drugs Standard Control Organization for Afrezza, the world's fastest inhaled insulin, offering a needle-free option for adults with type 1 and type 2 diabetes. This ultra-rapid-acting insulin works within 12 to 15 minutes of inhalation, closely mimicking the natural insulin response to meals and improving blood sugar control. Inhaled insulin presents a more comfortable alternative to daily injections, especially for patients with injection anxiety, enhancing adherence to insulin therapy.
In June 2022, Kindeva Drug Delivery Limited, a US-based pharmaceutical company, acquired iPharma Labs Inc. for an undisclosed amount. This acquisition allows Kindeva to integrate iPharma's expertise in inhalation formulations and early-stage drug development with its global capabilities in developing, commercializing, and manufacturing inhaled therapies. This combination strengthens Kindeva's position, enabling it to offer a more comprehensive, end-to-end solution for the development and manufacturing of respiratory medicines. iPharma Labs is a US-based contract research organization specializing in developing and formulating inhaled therapies, including inhalable biologics.
Major players in the inhalable biologics market are Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Medtronic PLC, Moderna Inc., Pfizer Inc. and BioNTech SE, Teva Pharmaceuticals, Baxter International, Lonza Group AG, CanSino Biologics Inc., Cipla Ltd., Insmed Incorporated, Kamada Pharmaceuticals, Vectura Group plc, F. Hoffmann-La Roche Ltd, Iconovo AB, Synairgen plc, Ab Initio Pharma LLC, Nanopharm Ltd, Ocugen Inc., MannKind Corporation.
North America was the largest region in the inhalable biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inhalable biologics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the inhalable biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The inhalable biologics market consists of sales of inhaled antibodies, inhalable mRNA-based therapeutics, inhaled vaccines, inhaled enzyme replacement therapies, and inhalable gene therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Inhalable Biologics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on inhalable biologics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for inhalable biologics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The inhalable biologics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Peptides And Proteins; Vaccines; Monoclonal Antibodies; RNAi-Based Therapeutics; Other Types
2) By Dosage Form: Dry Powder Inhalers; Metered Dose Inhalers; Nebulizers; Other Dosage Forms
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By Application: Respiratory Diseases; Diabetes; Cancer; Other Applications
Subsegments:
1) By Peptides And Proteins: Insulin; Growth Hormones; Enzyme Replacement Therapies; Other Peptides And Proteins
2) By Vaccines: Influenza Vaccines; Other Respiratory Vaccines
3) By Monoclonal Antibodies: Respiratory Monoclonal Antibodies; Immunomodulatory Monoclonal Antibodies; Other Monoclonal Antibodies
4) By RNAi-Based Therapeutics: RNA-Based Drugs For Respiratory Diseases; Other RNAi-Based Therapeutics
5) By Other Types: Gene Therapies; Small Molecule Inhalable Drugs; Other Innovative Inhalable Biologics
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Inhalable Biologics Market Characteristics
3. Inhalable Biologics Market Trends And Strategies
4. Inhalable Biologics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Inhalable Biologics Growth Analysis And Strategic Analysis Framework
5.1. Global Inhalable Biologics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Inhalable Biologics Market Growth Rate Analysis
5.4. Global Inhalable Biologics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Inhalable Biologics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Inhalable Biologics Total Addressable Market (TAM)
6. Inhalable Biologics Market Segmentation
6.1. Global Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Peptides And Proteins
Vaccines
Monoclonal Antibodies
RNAi-Based Therapeutics
Other Types
6.2. Global Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Dry Powder Inhalers
Metered Dose Inhalers
Nebulizers
Other Dosage Forms
6.3. Global Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.4. Global Inhalable Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Respiratory Diseases
Diabetes
Cancer
Other Applications
6.5. Global Inhalable Biologics Market, Sub-Segmentation Of Peptides And Proteins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Insulin
Growth Hormones
Enzyme Replacement Therapies
Other Peptides And Proteins
6.6. Global Inhalable Biologics Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Influenza Vaccines
Other Respiratory Vaccines
6.7. Global Inhalable Biologics Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Respiratory Monoclonal Antibodies
Immunomodulatory Monoclonal Antibodies
Other Monoclonal Antibodies
6.8. Global Inhalable Biologics Market, Sub-Segmentation Of RNAi-Based Therapeutics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
RNA-Based Drugs For Respiratory Diseases
Other RNAi-Based Therapeutics
6.9. Global Inhalable Biologics Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Gene Therapies
Small Molecule Inhalable Drugs
Other Innovative Inhalable Biologics
7. Inhalable Biologics Market Regional And Country Analysis
7.1. Global Inhalable Biologics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Inhalable Biologics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
